Way back in 2019, before most of us knew what a shroom stock was, MindMed made one of the first big moves in the psychedelic medicine industry by acquiring a drug candidate based on Ibogaine. The drug was 18-MC, a version of Ibogaine synthesized to be non-hallucinogenic while maintaining the medicine’s anti-addictive properties.
This was before any psychedelic medicine companies has gone public and MindMed began its journey here, with the acquisition of this anti-addiction compound.
Today, many years and market runs later, MindMed is finally moving this compound towards Phase 2 trials.
The Phase 1 results showed positive safety and tolerability results, the main objective of this phase of the trial process (and an important hurdle considering that natural Ibogaine has a history of adverse physical effects). See below for the full topline results.
According to MindMed, Phase 2a trial remains on track to start in Q2 2022. This follows on the heels of MindMed’s positive Phase 2 results using LSD for anxiety, giving the firm two Phase 2 trials for major conditions underway this year.
Stay tuned for more as it comes.
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal
NEWS PROVIDED BY
May 19, 2022, 07:30 ET
– Positive safety and tolerability results support the advancement of MM-110 and guide the Phase 2a dose design in individuals undergoing supervised opioid withdrawal
– Phase 2a trial remains on track to initiate in Q2 2022
NEW YORK, May 19, 2022 /CNW/ — Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced topline results from the Phase 1 placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics and neurocognitive effects of MM-110 in 108 healthy volunteers.
The results showed favorable safety and tolerability, support the advancement of MM-110, and have guided the Phase 2a dose, schedule, and design in individuals undergoing supervised opioid withdrawal. MM-110 (also known as zolunicant HCl or 18-MC) is an α3β4 nicotinic cholinergic receptor antagonist and non-hallucinogenic proprietary congener of ibogaine.
“As there is a major unmet need to address the ongoing and ever-growing opioid crisis, we are very pleased with the results from our Phase 1 trial, which underscore the potential clinical utility of MM-110 to safely mitigate symptoms of opioid withdrawal,” said Daniel R Karlin, MD MA, Chief Medical Officer of MindMed. “These data build on extensive pharmacology and toxicology studies, as well as encouraging results from preclinical studies that showed reductions in translational markers of opioid withdrawal and multi-day reductions in opioid self-administration following a single-dose administration of MM-110. Together, the data generated to date support our clinical development program and bring us one step closer to potentially providing an effective treatment solution with an optimized dosing schedule for withdrawal management. We look forward to leveraging these findings in the upcoming Phase 2a, gated two-part study, which will provide an opportunity for early signs of efficacy and inform the randomized proof-of-concept trial. The Phase 2a trial remains on track to initiate in the second quarter of 2022.”
A total of 72 participants received up to 325 mg of MM-110 (n=51) twice on a single day or placebo (n=21), and 36 participants were administered up to 90mg of MM-110 (n=26) twice daily for seven days or placebo (n=10). The topline results and observations include the following:
- MM-110 was well-tolerated
up to 500mg per day in the single ascending dose (SAD) arm and 60 mg per day for seven days in the multiple-ascending dose (MAD) arm of the trial.
- A linear pharmacokinetic profile was maintained across the tested doses and frequencies.
- Observed clinical effects demonstrated alignment with potent CNS engagement.
- No serious adverse events were reported. Treatment emergent adverse events were mild or moderate in severity and resolved without sequelae.
- Clinical laboratory parameters and electrocardiograms were also assessed with no findings of clinical concern across the administered dose ranges.
- Next steps: Consistent with the Phase 1 trial and aligned with the preclinical data, an every-other-day dose regimen is planned for the Phase 2a trial. This dose schedule offers the potential to be a better option than existing treatments for supervised opioid withdrawal.
About the Phase 1 Trial Design
The Phase 1 single and multiple-ascending dose trial conducted at a single clinical research site in Perth, Australia, evaluated the safety, tolerability, pharmacokinetics, and effects on the neurocognitive activity of MM-110 in 108 healthy volunteers.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
SOURCE Mind Medicine (MindMed) Inc.
